Search company, investor...
Search

Founded Year

2017

Stage

Incubator/Accelerator | Alive

Total Raised

$3.82M

Mosaic Score

+50 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Embleema

Embleema is a patient-centeric, tamper-proof, holistic, and longitudinal health record. It is a group of healthcare and technology veterans building using Blockchain and HL7 industry standards. Embleema's PatientTruth solution provides patients with their holistic medical history across the continuum of care and full control to share it with approved caregivers.

Embleema Headquarters Location

214 w 29 St 3rd Floor

New York, New York, 10001,

United States

+1 914 572 8108

Embleema's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Embleema's Products & Differentiation

See Embleema's products and how their products differentiate from alternatives and competitors

  • PRECISION RWD

    SaaS platform that collects any kind of clinical and real-world health data (clinical trial data, electronic medical records, patient generated data such as survey responses, connected devices, molecular data, unstructured data such as images, ECGs, EEGs) from any source (patient, investigator, health center, lab)

    Differentiation

    Richest data at the patient-level on the market. Ability to extend the data model in real-time. Ability to reach the patient in real-time for additional insights. 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Embleema

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Embleema in 1 CB Insights research brief, most recently on Jan 19, 2021.

Expert Collections containing Embleema

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Embleema is included in 4 Expert Collections, including Blockchain.

B

Blockchain

5,015 items

Companies and startups in this collection leverage blockchain technology for crypto trading, decentralized finance (DeFi), NFTs, and more.

C

Conference Exhibitors

5,302 items

D

Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

2,275 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Latest Embleema News

Embleema and CDISC Partner to Develop Standards for Cell and Gene Therapy Product Monitoring

May 24, 2022

Establishing Standards for Experimental Assays and Bioinformatics Protocols Aim at Accelerating Development and Availability of New Cell and Gene Therapies for Patients Download May 24, 2022 08:06 AM Eastern Daylight Time METUCHEN, N.J. & AUSTIN, Texas--( BUSINESS WIRE )--Embleema Inc. and CDISC have announced a collaboration to develop new standards for experimental assays and bioinformatics protocols to facilitate monitoring the activity of Cell and Gene Therapy Products (CGTP). CGTP involves inoculating patients with active ingredients such as proteins, genes, attenuated viruses, altered cells and other live tissues. Their activity inside patients is difficult to control, and the lack of standards for monitoring and analyzing this activity makes it difficult for sponsors to demonstrate the safety and efficacy of their products and impedes regulatory review. The collaboration will cover standards development in three areas: Protocols for experimental assays and bioinformatics pipelines for evidence generation and submission to the regulation bodies Provenance and privacy with relation to the patient CGTP datasets Longitudinal data linkage and patient engagement These new standards are intended to drive operational efficiencies, expediting the regulatory review process and reducing the time it takes to bring safe and effective treatments to market. “Through this partnership with CDISC, we are creating opportunities to accelerate drug development in personalized medicine and bring associated costs down,” said Vahan Simonyan, PhD, Chief Science Officer, Embleema. “We are hopeful patients will benefit greatly from this collaboration that will standardize approaches for cell and gene therapy evidence generation and expedite new treatments for patients.” “We are grateful for the opportunity to partner with CDISC Platinum Member Embleema in developing standards that will meet a crucial need,” said Rhonda Facile, VP, Partnerships and Development, CDISC. “Embleema’s innovative work, combined with CDISC’s established processes and procedures, will benefit the clinical research community and, ultimately, patients greatly.” Next steps include CDISC and Embleema working together to dimension and support development of standards for the three specified areas. Once released, the standards will be freely available via the CDISC website. About Embleema Embleema’s standard technology platform accelerates personalized medicine by expediting evidence generation and regulatory reviews of new treatments. From establishing trusted real-world and clinical data networks to making complex data sets regulatory grade, Embleema helps its clients from life sciences, academia, regulatory agencies, and patient advocacy build a healthier world. For more information, please visit www.embleema.com . About CDISC CDISC creates clarity in clinical research by convening a global community to develop and advance data standards of the highest quality. Required by the United States Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA) and adopted by the world’s leading research organizations, CDISC standards enable the accessibility, interoperability, and reusability of data. With the help of CDISC standards, the entire research community can maximize the value of data for more efficient and meaningful research that has invaluable impact on global health. CDISC is a 501(c)(3) global nonprofit charitable organization with administrative offices in Austin, Texas, and Brussels, Belgium and thousands of employees, volunteers, and member organizations around the world. https://www.cdisc.org/ Contacts

Embleema Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Embleema Rank

  • When was Embleema founded?

    Embleema was founded in 2017.

  • Where is Embleema's headquarters?

    Embleema's headquarters is located at 214 w 29 St, New York.

  • What is Embleema's latest funding round?

    Embleema's latest funding round is Incubator/Accelerator.

  • How much did Embleema raise?

    Embleema raised a total of $3.82M.

  • Who are the investors of Embleema?

    Investors of Embleema include MassChallenge, Alchemist Blockchain Techstars Accelerator, Pharmagest and Techstars Ventures.

  • Who are Embleema's competitors?

    Competitors of Embleema include DNAnexus and 3 more.

  • What products does Embleema offer?

    Embleema's products include PRECISION RWD and 1 more.

  • Who are Embleema's customers?

    Customers of Embleema include U.S. FDA and Eisai.

You May Also Like

LifeOmic Logo
LifeOmic

LifeOmic is the developer of a secure cloud service for the long-term storage, retrieval, analysis, and clinical use of information central to patient care. Its PHC platform integrates and indexes disparate sources including genomic, clinical, imaging, and population data. All of this data is added to a searchable and flexible repository for each patient to deliver precision treatments and accelerate research. LifeOmic's LIFE mobile apps use the Precision Health Clous to empower individuals to be more involved in and take action on their personal health and wellness goals.

K
Kelaroo

The KRMS aims to provide their organization with the tools needed to keep the key ingredients of research at their scientists' fingertips. Using the KRMS, researchers as well as stockroom, purchasing and EH&S personnel readily find, request, receive and track all chemical products. Inventory Management Reagent & Chemical Management for Pharma, BioTech, Manufacturers and Integrators (ELN, ERP, LIMS) Genome mining, sequence profiling and optimization Enhance their bioinformatics discovery program with SeqR. SeqR applies machine learning to public and sequence data to generate models with powerful sequence profiling abilities well suited to genome mining, sequence optimization, and SAR analysis.

L
Latch Bio

LatchBio offers a digital platform specializing in gene-editing bioinformatics. The company's platform can integrate with existing data stacks and visualize biological data all within browsers.

BC Platforms Logo
BC Platforms

BC Platforms specializes in bioinformatics and genome data management. BC Platforms provides genome data management and analysis solutions.

Lifebit Logo
Lifebit

Lifebit builds a cloud-based, cognitive system that can reason about DNA data like humans do. It aims to allow wider access to global biomedical data for drug discovery through the development of its clinico-genomic database.Per the company, it has a patented technology for federating genomic data in a way that allows researchers to get more insights while keeping the data secure.

Seven Bridges Logo
Seven Bridges

Seven Bridges is a biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development, and precision medicine. The company's cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical, and academic labs use Seven Bridges, including two of the largest genomics projects in the world: U.S. National Cancer Institute's Cancer Genomics Cloud pilot and Genomics England's 100,000 Genomes Project.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.